UnknownPHASE1, PHASE2NCT04101643

PCSK9 Inhibitor Treatment for Patients With SPG5

Studying Hereditary spastic paraplegia

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: First Affiliated Hospital of Fujian Medical University
Principal Investigator: Wan-Jin Chen
First Affiliated Hospital Fujian Medical University
Intervention: evolocumab(drug)
Enrollment: 30 enrolled
Eligibility: 14-80 years · All sexes
Timeline: 2019 – 2023

Study locations (1)

Department of Neurology , First Affiliated Hospital Fujian Medical University, Fuzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04101643 on ClinicalTrials.gov

Other trials for Hereditary spastic paraplegia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06692712
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
Elpida Therapeutics SPC

See all trials for Hereditary spastic paraplegia →

← Back to all trials